Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NamePurapharm
Stock Code01498
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities以香港為基地的領先中醫藥公司,以「農本方®」品牌從事濃縮中藥配方顆粒產品的研發、生產、市場推廣及銷售,並銷售金靈芝®及安固生®等中藥保健品。
Listing Date2015-07-08
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)香港新界大埔香港科學園1期無線電中心2樓201-207單位
Business Address (Hong Kong)香港中環康樂廣場1號怡和大廈4002室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitepurapharm.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 5.98 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer PeriodTo be extracted
Global Offering Shares71,130,000 shares
HK Public Offer Shares (Initial)7,113,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)64,017,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO225,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 425,357,400

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 148.2M
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +6454%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約34.5百萬港元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 46,800,000
Listing Expenses / Funds Raised~11.0%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 HKD
Income Statement
Item 201220132014
Revenue 287,811342,303366,352
Cost of sales -103,210-123,086-134,241
Gross profit 184,601219,217232,111
Other income and gains, net 13,9967,9565,794
Selling and distribution expenses -78,166-101,940-99,176
Administrative expenses -54,628-79,711-81,028
Operating profit 61,01242,83955,394
Net finance costs -10,959-13,149-13,064
Profit before tax 50,05329,69042,330
Income tax expense -5,911-3,399-7,823
Profit for the year 44,14226,29134,507
Profit attributable to owners 44,09426,26434,463
Balance Sheet
Item 201220132014
Cash and cash equivalents 36,83932,85246,736
Trade and bills receivables 67,32698,744103,098
Inventories 76,94365,21489,893
Total current assets 236,066240,214305,606
Total assets 333,502348,111420,310
Total current liabilities 286,806268,440282,575
Total liabilities 289,475274,999284,497
Total equity 44,02773,112135,813
Equity attributable to owners 43,97473,032135,689
Interest-bearing borrowings 179,839188,190182,692
Cash Flow Statement
Item 201220132014
Net cash from operating activities 62,12811,03431,091
Net cash from investing activities -37,793-6,268-24,634
Net cash from financing activities 2,1652,355-259
Net increase in cash 26,5007,1216,198
Depreciation of PP&E 9,84011,34612,749
Amortisation of intangible assets 394621837
Purchase of PP&E -13,426-17,187-8,586
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 3.83
First Day OpenHK$ 4.77
First Day Change-35.95%
First Day Volume20735500.0
First Day Turnover85492600.0
Use of Proceeds
1、約30.0%或86.7百萬港元將用作擴建生產設施及為現有生產線進行升級; 2、約25.0%或72.2百萬港元將用作在香港及中國成立新的農本方?中醫診所; 3、約20.0%或57.8百萬港元用作擴展我們的分銷網絡至中國的新目標城市,主要透過與國藥控股合作付諸實行,包括:(i)為新客戶購買農本方?智能中醫診所管理及配藥系統設備(每個藥房系統的平均成本為150,000港元);(ii)就農本方?智能中醫診所管理及配藥系統的運營及維護培訓新的分銷商及醫院員工;(iii)提供售后及維護服務;(iv)在中國的獲批準醫院及醫療機構成立及裝修我們從事直接銷售的中藥房; 4、約15.0%或43.3百萬港元用作為下列兩種新中成藥產品的開發及推廣(包括:(i)完成中國規定的臨床試驗;(ii)香港及中國的新產品注冊;及(iii)有關測試、抽樣及項目管理)提供資金; 5、約10.0%或28.9百萬港元將用作我們的營運資金及其他一般公司用途。

Underwriting Syndicate

Sole Sponsor (1)
BOCOM International (Asia) Limited CE API271
Overall Coordinators (1)
交银国际证券有限公司 CE APJ121
Joint Bookrunners (1)
交银国际证券有限公司 CE APJ121
Joint Lead Managers (2)
交银国际证券有限公司 CE APJ121 星展亚洲融资有限公司 CE AAE430

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman陳宇齡—
Company Secretary鄭學啟—
No director data available.

Major Shareholders

Major Shareholders & Holdings陳宇齡先生及文綺慧女士透過Purapharm Corp.、Fullgold Development及Joint Partners間接實益擁有合共57.28%權益;Fullgold Development持股34.35%,PuraPharm Corp.及Joint Partners各持股22.93%。
About this page

This page shows Purapharm (01498) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect